Pembrolizumab is: (A) CTLA4 inhibitor, (B) Monoclonal antibody against PDL1 receptor, (C) Monoclonal antibody against PD1 ligand, (D) Monochonal antibody against CDK416
Answer is B. Pembrolizumab and Nevolumab are monoclonal antibodies against PDL1 receptor used in BRAF -ve malignant melanoma.